Optimizing Spray Drying Strategies for Commercial Pharmaceutical Manufacturing

The use of spray drying to manufacture amorphous dispersions is continuing to grow due to the number of drug candidates exhibiting poor solubility. Apart from addressing solubility, spray drying is a reproducible processing technology that offers improved production efficiency that can potentially reduce cost and time-to-market. Phase-appropriate Quality by Design framework can increase the understanding of the interplay between the process parameters of spray drying and product quality that, when applied during scale-up, increases the chances of a successful outcome of the commercial manufacturing process. 

It is essential to select a robust formulation in the early phase for easier scale-up during development and manufacturing. Small-scale experiments, risk assessments and process development experience and knowledge are keys to a successful scale-up strategy. 

Register for this webinar to get insights from industry experts on:

• Determining when spray drying is the right technology for bioavailability enhancement
• The importance of process and formulation parameters that need to be addressed for successful commercial scale-up
• The importance of the optimization of process parameters and understanding possible pitfalls during execution
• How integrated services can minimize risk and save cost and time on development and manufacturing process

Speakers

Jon Scrafford, Director, Engineering & Continuous Improvement, Catalent

Jon Scrafford has worked at the Catalent’s San Diego site for more than six years. He began his career at Catalent as a process engineer and now manages the engineering and process improvement groups. He has expertise in process development, troubleshooting, and scale-up of solid oral dosage forms including blending, milling, wet/dry granulation, compression, coating and spray drying. Jon holds a Bachelor’s degree in Chemical Engineering with a minor in business from Northeastern University.

Message Presenter

Ryan Minikis, Principal, Arclight Pharmaceuticals, LLC

Ryan Minikis is currently principal at Arclight Pharmaceuticals, LLC, an independent consulting firm focusing on drug product development. Ryan previously held the position of senior director, North America PDS for Thermo Fisher Scientific (formerly Patheon) where he was responsible for the company’s pharmaceutical development services business across five North American drug product sites. Ryan also held positions at Agere Pharmaceuticals and Bend Research. Ryan’s formative work experience included assignments in analytical and formulation development, bioanalysis and quality control. His career has been focused on the understanding and application of drug-polymer systems involving drug product design across all therapeutic areas and delivery systems. Ryan earned a Bachelor’s degree in Chemistry as a Presidential Scholar from the University of Iowa. 

Message Presenter